Back

Angiotensin-converting enzyme inhibitors for the primary prevention of heart failure among adult patients on anthracycline-based chemotherapy: a meta-analysis

28 August 2017 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster session 5 - Chronic heart failure (CHF) Cardiotoxicity of drugs ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Ferdinand Gerodias

St. Luke's Medical Center, Quezon (Philippines)

31 More presentations in this session

Presentation thumbnail
Doctor C. Santos-Gallego (New York, US)
Abstract
Presentation thumbnail
Doctor M. Drozd (Wroclaw, PL)
Abstract
Presentation thumbnail
Assistant Professor H. Aoki (Uchinada, JP)
Abstract
Presentation thumbnail
Associate Professor A. Tase (Pitesti, RO)
Abstract Slides
Presentation thumbnail
Miss M. Lodi (Debrecen, HU)
Abstract Slides

Access the full session

Session thumbnail
Poster session 5 - Chronic heart failure (CHF)

The Event

Event poster

ESC Congress 2017

28 August 2017 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Cardioprotective effects of prophylactic ACE Inhibitors in anthracycline-based chemotherapy: a systematic review and meta-analysis
4 April 2025
thumbnail
Webinar
How to manage cancer therapy-related cardiovascular toxicity. ESC 2022 Clinical Practice Guidelines - Webinar Series
19 September 2022
thumbnail
Congress Presentation
Is there an association of anthracyclines with HFrEF and/or HFpEF in patients treated for breast cancer or lymphoma after 30 years of follow-up? Insights from the Rochester epidemiology project
31 August 2024
thumbnail
Congress Presentation
Cancer therapeutics-related heart failure from a cohort study using big data of electronic health record in japan.
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources